Results 131 to 140 of about 15,943 (150)
Some of the next articles are maybe not open access.

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics, 2022
Adriaan Volkers   +2 more
exaly  

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

New England Journal of Medicine, 2013
Bruce E Sands   +2 more
exaly  

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

New England Journal of Medicine, 2020
Vince B C Biemans, Frank Hoentjen
exaly  

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

New England Journal of Medicine, 2013
Bruce E Sands, Milan Lukas, Scott Lee
exaly  

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

New England Journal of Medicine, 2019
Bruce E Sands   +2 more
exaly  

Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study

The Lancet Gastroenterology and Hepatology, 2023
exaly  

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Clinical Gastroenterology and Hepatology, 2020
Parambir Dulai   +2 more
exaly  

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Gut, 2017
Bruce E Sands   +2 more
exaly  

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

Gut, 2019
Sebastian Zeissig   +2 more
exaly  

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Clinical Gastroenterology and Hepatology, 2017
Gilles Boschetti   +2 more
exaly  
previous   12  13  14  15  

Home - About - Disclaimer - Privacy